NNVC
$3.60
Nanoviricides
($.01)
(.28%)
NNVC
Earnings Whisper ®
N/A
Consensus:  $0.00
Revenue:  N/A
Monday
Feb 15
Score
Grade
Tweet Share Watch
Tweet Share Watch
Latest EPS

What do you expect when NNVC reports earnings?
Beat
Meet
Miss

Where is NNVC's stock price going from here?
Up
Flat
Down
Stock chart of NNVC
Analysts
Summary of analysts' recommendations for NNVC
Score
Grade
Pivots
Resistance
-
-
-

-

Support
-
-
-
Tweet
Growth
Description
NanoViricides, Inc. is a development stage company focused on creating special purpose nanomaterials for antiviral therapy. The Company's novel nanoviricide class of drug candidates are designed to specifically attack enveloped virus particles and to dismantle them. It also focuses on the development of drugs against a number of viral diseases including H1N1 swine flu, H5N1 bird flu, seasonal Influenza, HIV, oral and genital Herpes, viral diseases of the eye including EKC and herpes keratitis, Hepatitis C, Rabies, Dengue fever, and Ebola virus, among others. NanoViricides, Inc. is headquartered in West Haven, Connecticut.
Peers
InterCeptRegeneron PharmaceuticalsVertex PharmaceuticalsBioMarin PharmaceuticalBristol-Myers SquibbZoetisMerck & Co.PfizerJohnson & JohnsonEli Lilly